The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis

European Respiratory Journal

Volumn 51, Issue 2, 2018, Pages

  Araújo, David ^a   Shteinberg, Michal ^b   Aliberti, Stefano ^c,d   Goeminne, Pieter C ^e,f   Hill, Adam T ^g   Fardon, Thomas C ^h   Obradovic, Dusanka ⁱ   Stone, Glenda ^j   Trautmann, Marion ^j   Davis, Angela ^j   Dimakou, Katerina ^k   Polverino, Eva ^l,m   De Soyza, Anthony ^n,o   McDonnell, Melissa J ^o,p   Chalmers, James D ^h  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b CARMEL MEDICAL CENTER   (Israel)

^c UNIVERSITY OF MILAN   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f AZ Nikolaas   (Belgium)

^g ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^h UNIVERSITY OF DUNDEE   (United Kingdom)

ⁱ UNIVERSITY OF NOVI SAD   (Serbia)

^j Grifols Inc   (United States)

^k SOTIRIA GENERAL HOSPITAL   (Greece)

^l UNIVERSITY OF BARCELONA   (Spain)

^m HOSPITAL CLÍNIC   (Spain)

ⁿ FREEMAN HOSPITAL   (United Kingdom)

^o NEWCASTLE UNIVERSITY   (United Kingdom)

^p UNIVERSITY HOSPITAL GALWAY   (Ireland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRONCHIECTASIS; COHORT ANALYSIS; DISEASE BURDEN; DISEASE EXACERBATION; DISEASE SEVERITY; EUROPE; FEMALE; FORCED EXPIRATORY VOLUME; HAEMOPHILUS INFLUENZAE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITY OF LIFE; CLINICAL TRIAL; COMPLICATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

AGED; BRONCHIECTASIS; DISEASE PROGRESSION; EUROPE; FEMALE; HUMANS; ISRAEL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 85041453117     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01953-2017     Document Type: Article

References (30)

1. McShane PJ, Naureckas ET, Tino G, et al. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2013; 188: 647.
2. Chalmers JD, Smith MP, McHugh BJ, et al. Short-and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 186: 657-665.
3. Cole PJ. Inflammation: A two-edged sword-the model of bronchiectasis. Eur J Respir Dis Suppl 1986; 147: 6-15.
4. Whitters D, Stockley R. Immunity and bacterial colonisation in bronchiectasis. Thorax 2012; 67: 1006-1013.
5. Cullen L, McClean S. Bacterial adaptation during chronic respiratory infection. Pathogens 2015; 4: 66-89.
6. Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol 2013; 55: 27-34.
7. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
8. Aliberti S, Lonni S, Dore S, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J 2016; 47: 1113-1122.
9. Evans SA, Turner SM, Bosch BJ, et al. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J 1996; 9: 1601-1604.
10. Davies G, Wells AU, Doffman S, et al. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J 2006; 28: 974-979.
11. Finch S, McDonnell MJ, Abo-Leyah H, et al. a comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc 2015; 12: 1602-1611.
12. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: A long-term study assessing the factors influencing survival. Eur Respir J 2009; 34: 843-849.
13. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277-1284.
14. Martínez-Garcia MA, Soler-Cataluña JJ, Perpiña-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007; 132: 1565-1572.
15. King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007; 101: 1633-1638.
16. Ho PL, Chan KN, Ip MSM, et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest 1998; 114: 1594-1598.
17. Suarez-Cuartin G, Smith A, Abo-Leyah H, et al. Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis. Respir Med 2017; 128: 1-6.
18. McDonnell MJ, Jary HR, Perry A, et al. Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir Med 2015; 109: 716-726.
19. Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65: Suppl. 1, i1-i58.
20. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 14th informational supplement [CLSI document M100-S14]. Wayne, Clinical and Laboratory Standards Institute, 2004.
21. Chalmers JD, Goeminne P, Aliberti S, et al. The Bronchiectasis Severity Index: an international derivation and validation study. Am J Respir Crit Care Med 2014; 189: 576-585.
22. Wilson CB, Jones PW, O'Leary CJ, et al. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997; 156: 536-541.
23. Goeminne PC, Nawrot TS, Ruttens D, et al. Mortality in non-cystic fibrosis bronchiectasis: A prospective cohort analysis. Respir Med 2014; 108: 287-296.
24. Martínez-García MA, de Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014; 43: 1357-1367.
25. Spinou A, Fragkos KC, Lee KK, et al. The validity of health-related quality of life questionnaires in bronchiectasis: A systematic review and meta-analysis. Thorax 2016; 71: 683-694.
26. Wilson CB, Jones PW, O'Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997; 10: 1754-1760.
27. Vallières E, Tumelty K, Tunney MM, et al. Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis. Eur Respir J 2017; 49: 1600851.
28. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society Guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50: 1700629.
29. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): A randomised double blind placebo-controlled trial. Lancet 2012; 380: 660-667.
30. Hilliam Y, Moore MP, Lamont IL, et al. Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung. Eur Respir J 2017; 49: 1602108.